Increased serum RANTES in patients with systemic lupus erythematosus

Rheumatology International

Volumn 32, Issue 5, 2012, Pages 1231-1233

  Lu, Man Man ^a   Wang, Juan ^a   Pan, Hai Feng ^a   Chen, Gui Mei ^a   Li, Jing ^a   Cen, Han ^a   Feng, Chen Chen ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Disease activity; RANTES; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; LA ANTIBODY; RANTES; SM ANTIBODY;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL5; CHINA; COMPLEMENT C3; COMPLEMENT C4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84863612667     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1761-2     Document Type: Article

References (14)

1. Youinou PM, Lydyard PM, Mageed RA (2002) B cells underpin lupus immunopathology. Lupus 11:1-3
2. Lima G, Soto-Vega E, Atisha-Fregoso Y, Sánchez-Guerrero J, Vallejo M, Vargas-Alarcón G, Llorente L (2007) MCP-1, RANTES, and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Hum Immunol 68:980-5
3. Ye DQ, Yang SG, Li XP, Hu YS, Yin J, Zhang GQ, Liu HH, Wang Q, Zhang KC, Dong MX, Zhang XJ (2005) Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch Dermatol Res 297:108-13
4. Stasikowska O, Danilewicz M, Wagrowska-Danilewicz M (2007) The significant role of RANTES and CCR5 in progressive tub-ulointerstitial lesions in lupus nephropathy. Pol J Pathol 58:35-40
5. Lit LC, Wong CK, Tam LS, Li EK, Lam CW (2005) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65:209-15
6. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
7. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH et al. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630-40
8. Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM (1993) Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 151:2601-12
9. Cockwell P, Calderwood JW, Brooks CJ, Chakravorty SJ, Savage CO (2002) Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines. Nephrol Dial Transplant 17:734-44
10. Vilá LM, Molina MJ, Mayor AM, Cruz JJ, Ríos-Olivares E, Ríos Z (2007) Association of serum MIP-1a, MIP-1b, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 26:718-22
11. Eriksson C, Eneslätt K, Ivanoff J, Rantapää-Dahlqvist S, Sundqvist KG (2003) Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythe-matosus. Lupus 12:766-74
12. Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22:83-7
13. Liu CC, Danchenko N, Navratil JS, Nilson SE, Manzi S, Ahearn JM (2005) Mining the complement system for lupus biomarkers. Clin Appl Immunol 5:185-206
14. Liu CC, Ahearn JM (2009) The search for lupus biomarkers. Best Pract Res Clin Rheumatol 23:507-23